Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease.
PURPOSE
Monitoring of key markers for lung cancer detection and tracking of acquired drug resistance is critical for the management of the disease. We aim to ascertain the value of monitoring both total cell free DNA concentrations and mutant EGFR DNA content within diverse groups of individuals most vulnerable to the disease.


METHODS
We proposed longitudinal monitoring of circulating DNA using digital PCR. Circulating DNA present in peripheral blood can be obtained non-invasively and provide timely disease status update. 25 heavy smokers and 50 patients undergoing TKI therapy were recruited. Peripheral blood specimens were taken at different time points and their circulating DNA were analyzed and quantified.


RESULTS
Significant higher concentrations of total cell free DNA were detected when compared with healthy high-risk individuals. Levels were stable throughout the treatment cycles, which makes it potentially a useful tool for patient stratification. Concurrent mutant T790M DNA detection of lung cancer patients at baseline achieved 82 % concordance with matched tissue analysis. Samples initially negative for the T790M gene mutation that became positive during treatment were corroborated with a repeat biopsy. The results showed its usefulness for serial monitoring.


CONCLUSION
Monitoring of circulating DNA addresses the need for disease detection and shows the ability to capture the dynamic changes of the disease.
['Wei|Zhangjing|Z|', 'Shah|Nirej|N|', 'Deng|Chong|C|', 'Xiao|Xuehui|X|', 'Zhong|Tenglang|T|', 'Li|Xiansong|X|']
Drug resistance Non small cell lung cancer (NSCLC) T790M mutation cfDNA ctDNA